On Nov. 4, 2022, Pfizer and BioNTech announced updated data from a Phase 2/3 clinical trial demonstrating a robust neutralizing immune response one-month after a 30-ﾵg booster dose of the companiesﾒ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)).

Immune responses against BA.4/BA.5 sublineages were substantially higher for those who received the bivalent vaccine compared to the companiesﾒ original COVID-19 vaccine, with a similar safety and tolerability profile between both vaccines.